Immunotherapy to limit atherosclerosis

• Science
  • Leiden Academic Centre for Drug Research (LACDR)
  • BioTherapeutics
  • Cardiovascular and Metabolic Therapeutics

Immunotherapy to limit atherosclerosis-projects

• Science
  • Leiden Academic Centre for Drug Research (LACDR)
  • BioTherapeutics
  • Cardiovascular and Metabolic Therapeutics

Impaired barrier of inflammatory skin diseases

• Science
  • Leiden Academic Centre for Drug Research (LACDR)
  • BioTherapeutics
  • Biologics Formulation

Improving citizens’ participation in public service delivery: the possibilities of data dashboards

In shape for photoregulation

• Science
  • Leiden Institute of Chemistry (LIC)
  • Fundamental Research in Energy & Sustainability
  • Biophysical Organic Chemistry

In silico characterization of a GPCR focused library

• Science
  • Leiden Academic Centre for Drug Research (LACDR)
  • Cell Systems and Drug Safety
  • Medicinal Chemistry
  • Computational Drug Discovery

IN THE BEGINNING WAS THE SOUND

• Humanities
  • Academy of Creative and Performing Arts

In touch with the dead

• Archaeology
  • World Archaeology
  • Roman Provinces, Middle Ages and Modern Period

In vitro and in vivo evaluation of synergistic and opposing effects of Chinese herbal medicine and natural compounds on immuno-modulation.

• Science
  • European Center for Chinese Medicine and Natural compounds

In vivo tracking and biodistribution of protein aggregates

• Science
  • Leiden Academic Centre for Drug Research (LACDR)
  • BioTherapeutics
  • Biologics Formulation

INCLUDE: Knowledge Platform on Inclusive Development Policies

Inclusion and exclusion

• Social and Behavioural Sciences
  • Psychology
  • Social, Economic and Organisational Psychology

Inclusion in Sports: experiental expertise of (dis-)ability

• Social and Behavioural Sciences
  • Cultural Anthropology and Development Sociology

Inclusiveness and Diversity at LIACS

• Social and Behavioural Sciences
  • Cultural Anthropology and Development Sociology

Individualized dosing of aminoglycosides and glycopeptide antibiotics in (morbidly) obese patients (AMIGO)